A/Prof Amit Khot
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
82 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies
DOI: 10.1016/S2352-3026(26)00005-02026
Journal article
Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies.
DOI: 10.1182/bloodadvances.20250195632026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.20250166462026
Journal article
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial.
DOI: 10.1158/1078-0432.CCR-25-32162026
Journal article
Trial in Progress: QUINTESSENTIAL-2—a phase 3 Study of Arlocabtagene Autoleucel Versus Standard of Care in Adult Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Exposed to Lenalidomide
DOI: 10.1016/j.jtct.2025.12.2792026
Journal article
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
DOI: 10.1111/bjh.702382025
Journal article
Establishing Barriers to and Enablers of Nurse-Enabled Subcutaneous Therapy Self-Administration Programs for Patients With Myeloma: Protocol for a Qualitative Descriptive Study.
DOI: 10.2196/85053
RECENT SCHOLARLY WORKS
2025
Journal article
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial
DOI: 10.1093/infdis/jiaf2972025
Journal article
Rehabilitation after bone marrow transplant compared with usual care to improve patient outcomes (REBOOT): protocol for a randomised controlled trial
DOI: 10.1186/s12885-025-13898-32025
Journal article
Protocol for Fit4Transplant: iterative optimisation of an exercise prehabilitation service for haematological cancer patients using phase II adaptive trials and co-design
DOI: 10.1186/s12885-025-15027-6